Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 3/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 3/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.30 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21274331 | 1.00 | CDK9 (0.33) | CDK9PIM1DGAT1EGFRTBK1 | |
| SCHEMBL21274298 | 0.84 | CNR2 (0.34) | CDK9PIM1DGAT1RET | |
| SCHEMBL21274300 | 0.84 | CNR2 (0.34) | CDK9PIM1DGAT1RET | |
| SCHEMBL22801995 | 0.83 | MAPT (0.34) | CDK9PIM1DGAT1FLT3AXL | |
| SCHEMBL22801994 | 0.83 | MAPT (0.34) | CDK9PIM1DGAT1FLT3AXL | |
| SCHEMBL21274070 | 0.81 | ALDH1A1 (0.37) | CDK9FLT3RETPIK3CDPRKAB2 | |
| SCHEMBL21274072 | 0.81 | ALDH1A1 (0.37) | CDK9FLT3RETPIK3CDPRKAB2 | |
| SCHEMBL21268737 | 0.80 | MAPT (0.39) | JAK2FLT3 | |
| SCHEMBL21274332 | 0.80 | GPR119 (0.44) | LRRK2 | |
| SCHEMBL21268734 | 0.80 | MAPT (0.39) | JAK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | claimed |
| EP-3752150-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB Biopharma SRL (BE) | 2020-12-23 | — | — | EP | claimed |
| CN-112105357-A | Pharmaceutically acceptable 6,5 heterobicyclic derivatives | UCB生物制药有限责任公司 | 2020-12-18 | — | — | CN | claimed |
| WO-2019158731-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-08-22 | — | — | WO | claimed |
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
| EP-3752150-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB Biopharma SRL (BE) | 2020-12-23 | — | — | EP | disclosed |
| CN-112105357-A | Pharmaceutically acceptable 6,5 heterobicyclic derivatives | UCB生物制药有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2019158731-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | CDK9 2020/4885PIM1 3878/4885DGAT1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.